*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
Shows no cross-reactivity with recombinant human CD30. The antibody will stimulate the bioactivity of mouse splenic B cell proliferation in the presence of IL-4 and IL-5.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Batch dependent (Please refer to the vial label for the specific concentration.)
recombinant mouse CD30, extracellular domain, expressed in NSO cells.
Purified by affinity chromatography
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
tumor necrosis factor receptor superfamily, member 8 , Cd30 , D1S166E , Ki , Ki-1
CD30 Ligand (CD30L) is a type II membrane protein of the tumor necrosis factor (TNF) superfamily. It is expressed on the cell surface of activated T cells, B cells, and monocytes. CD30L is also constitutively expressed on granulocytes and medullary thymic epithelial cells. Recombinant mature mouse CD30L (199 amino acids) has a calculated molecular mass of approximately 22 kDa. Due to glycosylation, the recombinant protein migrates to approximately 30-45 kDa in SDS-PAGE under non-reducing and reducing conditions. Human and mouse CD30 ligand share approximately 70% sequence homology. The specific receptor for CD30L is CD30, a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkinis and Reed-Sternberg cells using monoclonal antibody Ki-1. The binding of CD30L to CD30 mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkinis disease and other CD30+ lymphomas and acts as a costimulatory molecule in thymic negative selection.